2024
Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act
Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024, 192: 19-27. PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.Peer-Reviewed Original ResearchFacility-level changesAffordable Care ActNon-expansion statesUrological cancer patientsProportion of patientsExpansion statesBaseline proportion of patientsUrologic cancer careHigh-income zip codesCancer patientsFactors associated with changesPre-post designCancer care centerPost-ACA periodMedicaid expansion statesMultivariate logistic regressionMedicaid-insured patientsCancer careUrological cancersZip codesCare ActMedicaid patientsMedicaidLogistic regressionCare centerArea Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma
Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaArea-level measuresRenal cell carcinomaPatient-level factorsSystemic therapyEthnic disparitiesRelative risk ratiosSocially vulnerable areasCell carcinomaMeasures of social vulnerabilityMedicare beneficiariesCohort studyFee-for-service Medicare Parts AOdds ratioReceipt of systemic therapyLogistic regressionArea-level characteristicsAssociated with lack of treatmentNon-Hispanic blacksRetrospective cohort studyIndividual-level demographicsNon-Hispanic whitesAssociated with disparitiesUS Medicare beneficiariesMeasures of disadvantage
2019
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
Huntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. Blood 2019, 134: 797. DOI: 10.1182/blood-2019-122054.Peer-Reviewed Original ResearchFirst-line settingChronic lymphocytic leukemiaFlatiron Health databaseECOG performance statusFirst-line treatmentEarly discontinuationMultivariable logistic regressionPerformance statusIbrutinib discontinuationSpeakers bureauClinical trialsCLL diagnosisCLL therapyLymphocytic leukemiaHealth databasesLogistic regressionBruton tyrosine kinase inhibitorsFirst-line ibrutinibUse of ibrutinibWorse performance statusPoor performance statusRetrospective cohort studyCommunity oncology settingClinical decision support toolCommunity oncology practices
2017
Use of Alternative Medicine for Cancer and Its Impact on Survival
Johnson SB, Park HS, Gross CP, Yu JB. Use of Alternative Medicine for Cancer and Its Impact on Survival. Journal Of The National Cancer Institute 2017, 110: djx145. PMID: 28922780, DOI: 10.1093/jnci/djx145.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBreast NeoplasmsChoice BehaviorColorectal NeoplasmsComorbidityComplementary TherapiesEducational StatusFemaleHumansIncomeLung NeoplasmsMaleNeoplasm StagingNorthwestern United StatesPacific StatesPatient PreferenceProstatic NeoplasmsResidence CharacteristicsSex FactorsSurvival RateConceptsConventional cancer treatmentsAlternative medicineColorectal cancerCox proportional hazards regressionGreater riskLower comorbidity scoreMultivariable logistic regressionProportional hazards regressionPatterns of utilizationHigher socioeconomic statusNonmetastatic breastComorbidity scoreHormone therapyCurable cancerHazards regressionLung cancerAM useAnticancer treatmentStage IICancerIndependent covariatesLogistic regressionPatientsCancer treatmentSocioeconomic status
2013
Measures of polypharmacy and chemotherapy toxicity in older adults with cancer.
Maggiore R, Feng T, Dale W, Gross C, Tew W, Mohile S, Owusu C, Klepin H, Lichtman S, Gajra A, McKoy J, Katheria V, Ramani R, Jayani R, Brown J, Hurria A. Measures of polypharmacy and chemotherapy toxicity in older adults with cancer. Journal Of Clinical Oncology 2013, 31: 9545-9545. DOI: 10.1200/jco.2013.31.15_suppl.9545.Peer-Reviewed Original ResearchPrevalence of polypharmacyPIM useChemotherapy toxicityOlder adultsGeriatric oncology populationAdverse clinical outcomesUnconditional logistic regressionAdverse drug eventsChi-square testInappropriate medicationsMedication useOncology populationPatient ageClinical outcomesDaily medicationInvasive cancerDrug eventsOutpatient populationGrade 3PolypharmacyReferent groupOlder personsSquare testLogistic regressionCancer
2012
Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity
Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, Gross CP. Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. Journal Of The National Cancer Institute 2012, 105: 25-32. PMID: 23243199, PMCID: PMC3536640, DOI: 10.1093/jnci/djs463.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiotherapyProstate cancerMedicare beneficiariesGenitourinary toxicityEarly toxicityProton radiotherapyMultivariable logistic regressionPatterns of careMain outcome measuresType of radiotherapyMedicare reimbursementClinical benefitRetrospective studyPRT patientsOutcome measuresComprehensive cohortPRT useIMRT patientsPatientsSociodemographic characteristicsRadiotherapyCancerLogistic regressionMonthsSignificant differencesProton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT.
Yu J, Soulos P, Cramer L, Roberts K, Herrin J, Potosky A, Gross C. Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT. Journal Of Clinical Oncology 2012, 30: 4651-4651. DOI: 10.1200/jco.2012.30.15_suppl.4651.Peer-Reviewed Original ResearchProstate cancer patientsSix monthsShort-term toxicityOne-yearCancer patientsPRT patientsProstate cancerProton radiotherapyLogistic regressionTreatment-related complicationsOne-year outcomesCumulative complication rateMultivariable logistic regressionPatient-reported outcomesPatterns of careConditional logistic regressionHigher socioeconomic statusGU complicationsGU toxicityComplication rateEarly toxicityDiagnosis codesLong-term effectsRadiation therapyMedicare populationFactors associated with life expectancy (LE) < 3 months (mo) among older adults receiving palliative chemotherapy (chemo).
Hurria A, Hardt M, Tew W, Mohile S, Owusu C, Gross C, Gajra A, Lichtman S, Katheria V, Ramani R, Zavala L, Klepin H. Factors associated with life expectancy (LE) < 3 months (mo) among older adults receiving palliative chemotherapy (chemo). Journal Of Clinical Oncology 2012, 30: 9034-9034. DOI: 10.1200/jco.2012.30.15_suppl.9034.Peer-Reviewed Original ResearchUnintentional weight lossPoor physical functionMultivariate logistic regressionAdvanced cancerLife expectancyPhysical functionWeight lossBivariate analysisLogistic regressionOlder adultsGeriatric assessment variablesMulti-site cohort studyLimited life expectancyPhysical function measuresFunctional status measuresOlder ptsPalliative chemoPalliative chemotherapyPalliative intentCohort studyPatient ageLow albuminFunctional statusOptimal treatmentRisk factorsAnemia and functional disability in older adults with cancer.
Owusu C, Tew W, Hardt M, Mohile S, Klepin H, Gross C, Gajra A, Lichtman S, Ramani R, Katheria V, Zavala L, Hurria A. Anemia and functional disability in older adults with cancer. Journal Of Clinical Oncology 2012, 30: 9109-9109. DOI: 10.1200/jco.2012.30.15_suppl.9109.Peer-Reviewed Original ResearchFunctional disabilityProspective studyOlder adultsMulti-center prospective studyUnintentional weight lossCorrection of anemiaRandomized-controlled trialPre-treatment variablesOlder ptsChemotherapy toxicityGeriatric assessmentPatient agePrimary outcomeMean HbFunctional statusInstrumental activitiesDaily livingAnemiaAdvanced stageMultivariate analysisAge 65Secondary analysisModifiable strategiesBivariate analysisLogistic regression
1999
Factors Affecting Prophylactic Oophorectomy in Postmenopausal Women
GROSS C, NICHOLSON W, POWE N. Factors Affecting Prophylactic Oophorectomy in Postmenopausal Women. Obstetrics And Gynecology 1999, 94: 962-968. DOI: 10.1097/00006250-199912000-00011.Peer-Reviewed Original ResearchConceptsVaginal hysterectomyConcomitant oophorectomyProphylactic oophorectomyTotal abdominal hysterectomyWomen 50 yearsHospital discharge databasePhysician practice styleCross-sectional studyMultiple logistic regressionType of procedureOophorectomy ratesAbdominal hysterectomyPostmenopausal womenPatient factorsSurgical morbidityNonclinical factorsDischarge databaseOvarian cancerOophorectomyHysterectomyCase volumeBenign conditionsPractice styleLogistic regressionIndependent effects